en · de · es · pt
assay-notes.peptides6823.com › Guide › Bremelanotide Background And Development — Questions and Answers

Bremelanotide Background And Development — Questions and Answers

By Editorial Desk · published 2025-09-29 · last reviewed 2025-11-19 · Guide

If you have been reading about Lactam bridge and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.

Last reviewed on 2025-11-19. Where a claim depends on a specific study, the study is described rather than over-claimed.

Bremelanotide Background And Development

Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.

Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.

Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.

Development History And Regulatory Status

PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.

Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.

Pt-141 at a glance

PropertyValueNotes
Chemical classSynthetic cyclic heptapeptideAnalogue of alpha-MSH
Molecular massApproximately 1025 DaPeptide-scale molecule
RouteSubcutaneous injectionIntranasal form used in early research
Common synonymsPT-141; bremelanotide acetateResearch code and salt form
Typical storage2-8 °C, protected from lightUnopened vial condition

Analytical Methods and Storage Practice

The lactam ring that closes the peptide backbone improves resistance to exopeptidase attack, but the molecule stays susceptible to hydrolysis and oxidation once dissolved. Degradation accelerates with temperature, extreme pH, and light exposure, and repeated freeze-thaw cycles promote aggregation and material loss. Lyophilized powder held desiccated at or below minus twenty degrees Celsius is the common way to keep reference material. Reconstituted solutions are generally kept cold and used within a short window because their stability is far lower than that of the dry solid.

Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.

Identity and purity testing for this peptide typically relies on reversed-phase high-performance liquid chromatography with ultraviolet detection, reported as area-percent purity. Mass spectrometry, usually in tandem mode, confirms molecular mass and supports quantification in biological matrices. Sequence confirmation may use peptide mapping after enzymatic digestion, while nuclear magnetic resonance and circular dichroism supply supplementary structural detail. No single technique establishes identity alone, so laboratories compare retention time, mass, and fragment pattern against a verified reference standard.

Related pages on this site

Receptor Mechanism and Trial Evidence

Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.

Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.

Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.

Handling Storage and Quality Control

Reconstitution is usually performed with sterile water or a dilute acetic acid solution, and the choice of solvent affects both dissolution speed and final pH. Complete dissolution should be confirmed by visual inspection before any aliquot is taken, since undissolved particles can concentrate in the sampling volume. Repeated freeze-thaw cycles are the most common cause of gradual loss of purity, so dividing a stock into single-use aliquots at the first opportunity is standard practice. Working solutions kept refrigerated are generally used within days rather than weeks.

Identity and purity are established with orthogonal methods rather than a single test. Reverse-phase high-performance liquid chromatography with ultraviolet detection gives a purity figure by area normalization, while mass spectrometry confirms the expected molecular ion. Amino acid analysis or peptide mapping can detect sequence errors that a mass value alone would miss, and residual counterion content is sometimes measured separately. Common impurities include truncated sequences, oxidized residues, and deamidated products; reporting them individually is more informative than a single composite purity number.

Lyophilized peptide arrives as a white to off-white cake or powder and is normally held at minus twenty degrees Celsius or colder for extended periods. Short-term bench work at ambient temperature is tolerable for minutes, not hours, because the solid is hygroscopic and picks up moisture that promotes hydrolysis. Vials should stay in a desiccator or a sealed bag with desiccant, protected from light, since aromatic residues in the sequence are susceptible to photo-oxidation. Inventory records that note arrival date and storage location reduce the chance of using degraded material.

Identity and Chemical Background

PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.

Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.

Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.

Notes from published material

=== Electoral regulations === With 46 votes in favor, 50 against, and 28 abstentions, Congress approved the creation of a commission to investigate alleged electoral fraud in the 2021 Peruvian general election Allegations of electoral fraud were denied by the National Office of Electoral Processes, the National Jury of Elections, the OAS, the United States, and the European Union. Later, Congress green-lit a motion to change the electoral rules for the 2022 Peruvian municipal and regional elections. Because it is prohibited to modify electoral rules when the election is less than a year away, the Constitutional Committee has little time to pass new regulations. Previously, an attempt to suspend open primary elections for the 2022 regional and municipal elections failed, due to it only getting 45 votes in favor.

Adenosine-to-inosine (A-to-I) modifications contribute to nearly 90% of all editing events in RNA. The deamination of adenosine is catalyzed by the double-stranded RNA-specific adenosine deaminase (ADAR), which typically acts on pre-mRNAs. The deamination of adenosine to inosine disrupts and destabilizes the dsRNA base pairing, therefore rendering that particular dsRNA less able to produce siRNA, which interferes with the RNAi pathway. The wobble base pairing causes deaminated RNA to have a unique but different structure, which may be related to the inhibition of the initiation step of RNA translation. Studies have shown that I-RNA (RNA with many repeats of the I-U base pair) recruits methylases that are involved in the formation of heterochromatin and that this chemical modification heavily interferes with miRNA target sites. There is active research into the importance of A-to-I modifications and their purpose in the novel concept of epitranscriptomics, in which modifications are made to RNA that alter their function. A long established consequence of A-to-I in mRNA is the interpretation of I as a G, therefore leading to functional A-to-G substitution, e.g. in the interpretation of the genetic code by ribosomes. Newer studies, however, have weakened this correlation by showing that inosines can also be decoded by the ribosome (although in a lesser extent) as adenosines or uracils. Furthermore, it was shown that I's lead to the stalling of ribosomes on the I-rich mRNA.

In November 1998, Layne Staley recorded a cover of Pink Floyd's "Another Brick in the Wall" with the supergroup Class of '99. The song was featured on the soundtrack to the 1998 horror/sci-fi film, The Faculty. After they toured as part of Cantrell's solo band in 1998, Sean Kinney and Queensrÿche guitarist Chris DeGarmo formed a new band called Spys4Darwin. Mike Inez and Sponge lead vocalist Vin Dombroski joined the supergroup soon after. The band released their first and only album in 2001, a 6-track EP entitled Microfish. In June 2001, Mike Inez joined Zakk Wylde's Black Label Society for the remaining dates of Ozzfest, following the departure of bassist Steve Gibb for medical reasons. Inez joined the band again for their West Coast and Japanese tour in 2003. By 2002, Cantrell had finished work on his second solo album, Degradation Trip. Written in 1998, the album's lyrical content focused heavily on what Cantrell regarded as the demise of Alice in Chains, which still remained evident as the album approached its June 2002 release. However, in March that year, Cantrell commented, "We're all still around, so it's possible [Alice in Chains] could all do something someday, and I fully hope someday we will."

Sources: en.wikipedia.org

Further detail

putative gene A specific nucleotide sequence suspected to be a functional gene based on the identification of its open reading frame. The gene is said to be "putative" in the sense that no function has yet been described for its products.

=== Magnetic confinement fusion === MHD describes a wide range of physical phenomena occurring in fusion plasmas in devices such as tokamaks and stellarators. The Grad-Shafranov equation, derived from ideal MHD, describes the equilibrium of axisymmetric toroidal plasma in a tokamak. In tokamak experiments, the equilibrium during each discharge is routinely calculated and reconstructed, providing information on the shape and position of the plasma controlled by currents in external coils. MHD stability theory governs the operational limits of tokamaks. For example, ideal MHD kink modes provide hard limits on the achievable plasma beta (Troyon limit) and plasma current (set by the

Two people were killed by Russian shelling in Ukrainsk, Donetsk Oblast. One person was killed in a separate attack in Komar. Russia launched an air attack on Myrhorod Air Base in Poltava Oblast. The Ukrainian Air Force acknowledged damage, with two of the base's six Su-27s destroyed by an Iskander missile with a cluster warhead. A drone attack was reported in Sevastopol and other parts of Crimea, with the Ukrainian Air Force later claiming to have struck an ammunition dump using six Storm Shadow cruise missiles. The ammunition dump was also believed to host a "Shahed drone warehouse". Russian sources claimed that five aerial targets were shot down. Ukrainian drone attacks left parts of Belgorod Oblast without power. Ukrainian media reported that a drone strike the Oskol Electrometallurgical Plant, Russia's only full-cycle metallurgical enterprise, in Stary Oskol. Scouts from the Ukrainian Rubizh Brigade captured "several dozen Russian soldiers", mostly mobilised conscripts, in an unspecified location. Dutch defence minister Kajsa Ollongren announced that the export permits allowing the export of 24 F-16s to Ukraine had been granted, with their arrival set on a "confidential" date. The SBU claimed to have foiled a coup by a Russian-backed group against the Ukrainian government that was scheduled on 30 July. Russia claimed to have captured an ATACMS missile guidance system intact and was studying it to "identify any weak spots".

The life science training pathway for clinical scientists follows a similar pathway to that undertaken by medically qualified specialist registrars in pathology. Clinical scientists are therefore the only discipline of non-medical healthcare professionals examined by a Medical Royal College. Clinical scientists who attain both part 1 examination certification and part 2 certification are awarded Fellowship of the Royal College of Pathologists (FRCPath) and are deemed to have the knowledge and expertise expected of a consultant level scientist. Consultant clinical scientist posts generally require candidates to have completed FRCPath qualification to be eligible. All clinical scientists regardless of seniority or specialisation may have other responsibilities including academic appointments, responsibilities as clinical lead for a pathology service, or may have wider hospital responsibilities such as directorship of Infection Prevention and Control, or responsibility for the hospital's Research and Development strategy. Junior clinical scientists may become involved in academic research, working towards a Ph.D. or DClinSci.

Sources: en.wikipedia.org

Supporting material

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy. It was initially regarded as a form of lymphocyte-derived cutaneous lymphoma and alternatively named CD4+CD56+ hematodermic tumor, blastic NK cell lymphoma, and agranular CD4+ NK cell leukemia. Later, however, the disease was determined to be a malignancy of plasmacytoid dendritic cells rather than lymphocytes and therefore termed blastic plasmacytoid dendritic cell neoplasm. In 2016, the World Health Organization designated BPDCN to be in its own separate category within the myeloid class of neoplasms. It is estimated that BPDCN onstitutes 0.44% of all hematological malignancies. Blastic plasmacytoid dendritic cell neoplasm is an aggressive malignancy with features of cutaneous lymphoma (e.g. malignant plasmacytoid dendritic cell infiltrations into the skin to form single or multiple lesions) and/or leukemia (i.e. malignant plasmacytoid dendritic cells in blood and bone marrow). While commonly presenting with these clinical features, BPDCN, particularly in its more advanced stages, may also involve malignant plasmacytoid dendritic cell infiltrations in and thereby injury to the liver, spleen, lymph nodes, central nervous system, or other tissues. The neoplasm occurs in individuals of all ages but predominates in the elderly; in children, it afflicts males and females equally but in adults is far more common (~75% of cases) in males. Blastic plasmacytoid dendritic cell neoplasm typically responds to chemotherapy regimens used to treat hematological malignancies.

== Public consumption == The center at the Ames Research Center in California began researching how to allow visitors to taste astronaut food in 1973. They contacted American Outdoor Products and Backpacker's Pantry, the latter becoming a known source for freeze-dried meals like stews and even pasta dishes for serious campers and backpackers. NASA/AMES worked with American Outdoor Products to produce the world first freeze-dried ice cream and Astronaut Foods with the goal to allow people to see what space food tastes like.

=== Anesthesia === Sodium thiopental is an ultra-short-acting barbiturate and has been used commonly in the induction phase of general anesthesia. Its use has been largely replaced with that of propofol, but may retain some popularity as an induction agent for rapid-sequence induction and intubation, such as in obstetrics. Following intravenous injection, the drug rapidly reaches the brain and causes unconsciousness within 30–45 seconds. At one minute, the drug attains a peak concentration of about 60% of the total dose in the brain. Thereafter, the drug distributes to the rest of the body, and in about 5–10 minutes the concentration in the brain is low enough that consciousness returns. A normal dose of sodium thiopental (usually 4-6 mg/kg) given to a pregnant person for operative delivery (caesarean section) rapidly makes them unconscious, but the baby in their uterus remains conscious. However, larger or repeated doses can depress the baby's consciousness. Sodium thiopental is not used to maintain anesthesia in surgical procedures because, in infusion, it displays zero-order elimination pharmacokinetics, leading to a long period before consciousness is regained. Instead, anesthesia is usually maintained with an inhaled anesthetic (gas) agent. Inhaled anesthetics are eliminated relatively quickly, so stopping the inhaled anesthetic allows rapid return of consciousness. Sodium thiopental would have to be given in large amounts to maintain unconsciousness during anaesthesia due to its rapid redistribution throughout the body (as it has a high volume of distribution).

Sources: en.wikipedia.org

Frequently asked questions

What is bremelanotide?

It is a synthetic cyclic peptide that activates melanocortin receptors. It is given by injection and was approved in the United States in 2019 for a specific low-desire diagnosis in premenopausal women. It is not a hormonal therapy.

How does it differ from earlier options for low desire?

Earlier approaches were largely hormonal or psychological in focus, whereas this compound acts on central melanocortin signalling. It is not a vasodilator and does not share the mechanism of phosphodiesterase inhibitors. Head-to-head comparative data are limited.

Why are effect sizes discussed so carefully?

Placebo responses in desire trials are large, so the average drug-placebo separation is small. Reporting therefore relies on validated questionnaires with statistical ranges. Individual responses vary widely.

What is PT-141?

PT-141 is a research code for bremelanotide, a cyclic peptide that activates melanocortin receptors. It was developed for sexual dysfunction and later approved under a brand name as a subcutaneous injection. The same code is widely used by suppliers selling non-pharmaceutical material.

Network